{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:33:36Z","timestamp":1789180416530,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04399-3","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T16:00:46Z","timestamp":1755532846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The potential adding therapeutic effect of pentoxifylline and\/or folic acid for chronic kidney disease patients: randomized controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Amira Reda Muhammad","family":"Galal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla Mohamed","family":"Teama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3870-3206","authenticated-orcid":false,"given":"Karema","family":"Abu\u2013Elfotuha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed D.","family":"Alatawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1264-7229","authenticated-orcid":false,"given":"Hanan","family":"Alshareef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-792X","authenticated-orcid":false,"given":"Ahmed M. E.","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-9826","authenticated-orcid":false,"given":"Ahmed","family":"Aljabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohannad","family":"Alshibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab AlKasaby Mahmoud","family":"Zalat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"1S","key":"4399_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"105","author":"BH Rovin","year":"2024","unstructured":"Rovin BH, Ayoub IM, Chan TM, Liu ZH, Mej\u00eda-Vilet JM, Floege J. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105(1S):S1\u201369.","journal-title":"Kidney Int"},{"issue":"3","key":"4399_CR2","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/S2214-109X(24)00050-0","volume":"12","author":"M Jadoul","year":"2024","unstructured":"Jadoul M, Aoun M, Imani MM. The major global burden of chronic kidney disease. Lancet Glob Health. 2024;12(3):e342\u20133.","journal-title":"Lancet Glob Health"},{"issue":"9","key":"4399_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41581-024-00863-9","volume":"20","author":"NC Chesnaye","year":"2024","unstructured":"Chesnaye NC, Ortiz A, Zoccali C, Stel VS, Jager KJ. The impact of population ageing on the burden of chronic kidney disease. Nat Rev Nephrol. 2024;20(9):569\u201385.","journal-title":"Nat Rev Nephrol"},{"issue":"10302","key":"4399_CR4","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","volume":"398","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786\u2013802.","journal-title":"Lancet"},{"issue":"21","key":"4399_CR5","doi-asserted-by":"publisher","first-page":"11453","DOI":"10.3390\/ijms222111453","volume":"22","author":"E Gusev","year":"2021","unstructured":"Gusev E, Solomatina L, Zhuravleva Y, Sarapultsev A. The pathogenesis of End-Stage renal disease from the standpoint of the theory of general pathological processes of inflammation. Int J Mol Sci. 2021;22(21):11453.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"4399_CR6","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","volume":"119","author":"C Zoccali","year":"2023","unstructured":"Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, Agarwal R, Mark PB, Kotanko P, Ferro CJ, Wanner C, Burnier M, Vanholder R, Wiecek A. Cardiovascular complications in chronic kidney disease: a review from the European renal and cardiovascular medicine working group of the European renal association. Cardiovasc Res. 2023;119(11):2017\u201332.","journal-title":"Cardiovasc Res"},{"issue":"11","key":"4399_CR7","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.2215\/CJN.05880420","volume":"15","author":"A Ju","year":"2020","unstructured":"Ju A, Teixeira-Pinto A, Tong A, Smith AC, Unruh M, Davison SN, Dapueto J, Dew MA, Fluck R, Germain MJ, Jassal SV, Obrador, G T, O\u2019Donoghue D, Viecelli AK, Strippoli G, Ruospo M, Timofte D, Sharma A, Au E, Howell M, Costa DS, Anumudu S, Craig JC, Rutherford C. Validation of a core Patient-Reported outcome measure for fatigue in patients receiving hemodialysis: the SONG-HD fatigue instrument. Clin J Am Soc Nephrol. 2020;15(11):1614\u201321.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4399_CR8","doi-asserted-by":"publisher","first-page":"112399","DOI":"10.1016\/j.biopha.2021.112399","volume":"145","author":"SM El-Haggar","year":"2022","unstructured":"El-Haggar SM, Hegazy SK, Abd-Elsalam SM, Bahaa MM. Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with Mebeverine. Biomed Pharmacother. 2022;145:112399.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"4399_CR9","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1007\/s10787-024-01560-6","volume":"32","author":"MM Bahaa","year":"2024","unstructured":"Bahaa MM, Hegazy SK, Maher MM, Bahgat MM, El-Haggar SM. Pentoxifylline in patients with ulcerative colitis treated with Mesalamine by modulation of IL-6\/STAT3, ZO-1, and S1P pathways: a randomized controlled double-blinded study. Inflammopharmacology. 2024;32(5):3247\u201358.","journal-title":"Inflammopharmacology"},{"issue":"10","key":"4399_CR10","first-page":"CD005262","volume":"10","author":"C Broderick","year":"2020","unstructured":"Broderick C, Forster R, Abdel-Hadi M, Salhiyyah K. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2020;10(10):CD005262.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"4399_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4093\/dmj.2021.0329","volume":"46","author":"CY Jung","year":"2022","unstructured":"Jung CY, Yoo TH. Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease. Diabetes Metab J. 2022;46(2):181\u201397.","journal-title":"Diabetes Metab J"},{"issue":"2","key":"4399_CR12","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/jcm9020458","volume":"9","author":"J Donate-Correa","year":"2020","unstructured":"Donate-Correa J, Luis-Rodr\u00edguez D, Mart\u00edn-N\u00fa\u00f1ez E, Tagua VG, Hern\u00e1ndez-Carballo C, Ferri C, Rodr\u00edguez-Rodr\u00edguez AE, Mora-Fern\u00e1ndez C, Navarro-Gonz\u00e1lez JF. Inflammatory targets in diabetic nephropathy. J Clin Med. 2020;9(2):458.","journal-title":"J Clin Med"},{"issue":"3","key":"4399_CR13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10787-022-00993-1","volume":"30","author":"G Mostafa-Hedeab","year":"2022","unstructured":"Mostafa-Hedeab G, Al-Kuraishy HM, Al-Gareeb AI, Jeandet P, Saad HM, Batiha GE. A Raising dawn of Pentoxifylline in management of inflammatory disorders in Covid-19. Inflammopharmacology. 2022;30(3):799\u2013809.","journal-title":"Inflammopharmacology"},{"issue":"7","key":"4399_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/molehr\/gax029","volume":"23","author":"L Ly","year":"2017","unstructured":"Ly L, Chan D, Aarabi M, Landry M, Behan NA, MacFarlane AJ, Trasler J. Intergenerational impact of paternal lifetime exposures to both folic acid deficiency and supplementation on reproductive outcomes and imprinted gene methylation. Mol Hum Reprod. 2017;23(7):461\u201377.","journal-title":"Mol Hum Reprod"},{"issue":"16","key":"4399_CR15","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.3390\/nu15163616","volume":"15","author":"CW Chan","year":"2023","unstructured":"Chan CW, Lin BF. Folate deficiency enhanced inflammation and exacerbated renal fibrosis in High-Fat High-Fructose Diet-Fed mice. Nutrients. 2023;15(16):3616.","journal-title":"Nutrients"},{"issue":"1","key":"4399_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1590\/1806-9282.62.01.90","volume":"62","author":"S C Liew","year":"2016","unstructured":"C Liew S. Folic acid and diseases - supplement it or not? Rev Assoc Med Bras (1992). 2016;62(1):90\u2013100.","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"4","key":"4399_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000471813","volume":"7","author":"G Cianciolo","year":"2017","unstructured":"Cianciolo G, De Pascalis A, Di Lullo L, Ronco C, Zannini C, La Manna G. Folic acid and homocysteine in chronic kidney disease and cardiovascular disease progression: which comes first. ? Cardiorenal Med. 2017;7(4):255\u201366.","journal-title":"? Cardiorenal Med"},{"issue":"1","key":"4399_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12882-023-03295-y","volume":"24","author":"W Chen","year":"2023","unstructured":"Chen W, Feng J, Ji P, Liu Y, Wan H, Zhang J. Association of hyperhomocysteinemia and chronic kidney disease in the general population: a systematic review and meta-analysis. BMC Nephrol. 2023;24(1):247.","journal-title":"BMC Nephrol"},{"key":"4399_CR19","doi-asserted-by":"crossref","unstructured":"Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015,14,6.","DOI":"10.1186\/1475-2891-14-6"},{"issue":"4","key":"4399_CR20","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms22041690","volume":"22","author":"F Paganelli","year":"2021","unstructured":"Paganelli F, Mottola G, Fromonot J, Marlinge M, Deharo P, Guieu R, Ruf J. Hyperhomocysteinemia and cardiovascular disease: is the adenosinergic system the missing link?? Int J Mol Sci. 2021;22(4):1690.","journal-title":"Int J Mol Sci"},{"issue":"9212","key":"4399_CR21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(00)02124-3","volume":"355","author":"J Volmink","year":"2000","unstructured":"Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet. 2000;355(9212):1345\u201350.","journal-title":"Lancet"},{"key":"4399_CR22","first-page":"1","volume":"22","author":"C Oedingen","year":"2025","unstructured":"Oedingen C, van Gestel R, Huls SP, Granic G, de Bekker-Grob EW, Veldwijk J. Association of medication adherence with treatment preferences: incentivizing truthful self-reporting. Eur J Health Econ. 2025;22:1\u20134.","journal-title":"Eur J Health Econ"},{"issue":"Suppl 1","key":"4399_CR23","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1136\/oem.60.suppl_1.i10","volume":"60","author":"J De Vries","year":"2003","unstructured":"De Vries J, Michielsen HJ, Van Heck GL. Assessment of fatigue among working people: a comparison of six questionnaires. Occup Environ Med. 2003;60(Suppl 1):i10\u20135.","journal-title":"Occup Environ Med"},{"issue":"11","key":"4399_CR24","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/nrd2685","volume":"7","author":"N Perico","year":"2008","unstructured":"Perico N, Benigni A, Remuzzi G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nat Rev Drug Discov. 2008;7(11):936\u201353.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"4399_CR25","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/sj.ki.5000302","volume":"69","author":"YM Chen","year":"2006","unstructured":"Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int. 2006;69(8):1410\u20135.","journal-title":"Kidney Int"},{"issue":"1","key":"4399_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.18388\/abp.2010_2383","volume":"57","author":"M Renke","year":"2010","unstructured":"Renke M, Tylicki L, Rutkowski P, Knap N, Zietkiewicz M, Neuwelt A, Aleksandrowicz E, \u0141ysiak-Szyd\u0142owska W, Wo\u017aniak M, Rutkowski B. Effect of Pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. Acta Biochim Pol. 2010;57(1):119\u201323.","journal-title":"Acta Biochim Pol"},{"issue":"4","key":"4399_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1053\/j.ajkd.2008.11.026","volume":"53","author":"RM Perkins","year":"2009","unstructured":"Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of Pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2009;53(4):606\u201316.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"4399_CR28","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/imj.13060","volume":"46","author":"WR Adam","year":"2016","unstructured":"Adam WR, Wright JR. Use of Renin angiotensin system inhibitors in patients with chronic kidney disease. Intern Med J. 2016;46(5):626\u201330.","journal-title":"Intern Med J"},{"issue":"3","key":"4399_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10557-018-6802-1","volume":"32","author":"M Goicoechea","year":"2018","unstructured":"Goicoechea M, de Vinuesa SG, Quiroga B, Verde E, Bernis C, Morales E, Fern\u00e1ndez-Ju\u00e1rez G, de Sequera P, Verdalles U, Delgado R, Torres A, Arroyo D, Abad S, Ortiz A, Lu\u00f1o J. Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study). Cardiovasc Drugs Ther. 2018;32(3):255\u201363.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"4399_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/j.ajkd.2014.06.020","volume":"65","author":"DW Johnson","year":"2015","unstructured":"Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM. HERO study collaborative group. A randomized, placebo-controlled trial of Pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the handling erythropoietin resistance with oxpentifylline (HERO) trial. Am J Kidney Dis. 2015;65(1):49\u201357.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"4399_CR31","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/archinte.167.12.1262","volume":"167","author":"PW Nanayakkara","year":"2007","unstructured":"Nanayakkara PW, van Guldener C, ter Wee PM, Scheffer PG, van Ittersum FJ, Twisk JW, Teerlink T, van Dorp W, Stehouwer CD. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine Lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant therapy in chronic renal insufficiency (ATIC) study. Arch Intern Med. 2007;167(12):1262\u201370.","journal-title":"Arch Intern Med"},{"issue":"6","key":"4399_CR32","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00467-018-4005-4","volume":"34","author":"K Daenen","year":"2019","unstructured":"Daenen K, Andries A, Mekahli D, Van Schepdael A, Jouret F, Bammens B. Oxidative stress in chronic kidney disease. Pediatr Nephrol. 2019;34(6):975\u201391.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"4399_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1179\/1351000215Y.0000000022","volume":"21","author":"L Zhang","year":"2016","unstructured":"Zhang L, Coombes J, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW. On behalf of the hero study collaborative group. the effect of Pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hypo responsiveness: Sub-study of the HERO trial. Redox Rep. 2016;21(1):14\u201323.","journal-title":"Redox Rep"},{"issue":"16","key":"4399_CR34","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1001\/jama.2010.490","volume":"303","author":"AA House","year":"2010","unstructured":"House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA. 2010;303(16):1603\u20139.","journal-title":"JAMA"},{"issue":"9","key":"4399_CR35","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.3390\/nu11092192","volume":"11","author":"H Yang","year":"2019","unstructured":"Yang H, Juang SY, Liao KF, Chen YH. Comparing the effect of folic acid and Pentoxifylline on delaying Dialysis initiation in patients with advanced chronic kidney disease. Nutrients. 2019;11(9):2192.","journal-title":"Nutrients"},{"issue":"8","key":"4399_CR36","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/00325481.2024.2426448","volume":"136","author":"H Zakaria","year":"2024","unstructured":"Zakaria H, Hamdy NA, Sayed-Ahmed NA, El-Mallah A. Pentoxifylline improves anemia through its novel effect on hypoxia-inducible factor-2 alpha in Hemodialysis patients: a randomized, double-blind, placebo-controlled clinical trial. Postgrad Med. 2024;136(8):847\u201354.","journal-title":"Postgrad Med"},{"issue":"3","key":"4399_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/jcm8030287","volume":"8","author":"J Donate-Correa","year":"2019","unstructured":"Donate-Correa J, Tagua VG, Ferri C, Mart\u00edn-N\u00fa\u00f1ez E, Hern\u00e1ndez-Carballo C, Ure\u00f1a-Torres P, Ruiz-Ortega M, Ortiz A, Mora-Fern\u00e1ndez C, Navarro-Gonz\u00e1lez JF. Pentoxifylline for renal protection in diabetic kidney disease. A model of old drugs for new horizons. J Clin Med. 2019;8(3):287.","journal-title":"J Clin Med"},{"issue":"2","key":"4399_CR38","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/bjd.15375","volume":"177","author":"I Skoie","year":"2017","unstructured":"Skoie I, Dalen I, Ternowitz T, Jonsson G, Kvivik I, Norheim K. Omdal R. Fatigue in psoriasis: a controlled study. Br J Dermatol. 2017;177(2):505\u201312.","journal-title":"Br J Dermatol"},{"issue":"9","key":"4399_CR39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/ijd.15341","volume":"60","author":"MO Machado","year":"2021","unstructured":"Machado MO, Kang NC, Tai F, Sambhi RDS, Berk M, Carvalho AF, Chada LP, Merola JF, Piguet V, Alavi A. Measuring fatigue: a meta-review. Int J Dermatol. 2021;60(9):1053\u201369.","journal-title":"Int J Dermatol"},{"issue":"6","key":"4399_CR40","doi-asserted-by":"publisher","first-page":"376","DOI":"10.5455\/medarh.2015.69.376-380","volume":"69","author":"S Zyga","year":"2015","unstructured":"Zyga S, Alikari V, Sachlas A, Fradelos EC, Stathoulis J, Panoutsopoulos G, Georgopoulou M, Theophilou P, Lavdaniti M. Assessment of fatigue in end stage renal disease patients undergoing hemodialysis: prevalence and associated factors. Med Arch. 2015;69(6):376\u201380.","journal-title":"Med Arch"},{"key":"4399_CR41","doi-asserted-by":"publisher","unstructured":"Navarro-Gonz\u00e1lez JF, S\u00e1nchez-Ni\u00f1o MD, Donate-Correa J, Mart\u00edn-N\u00fa\u00f1ez E, Ferri C, P\u00e9rez-Delgado N, G\u00f3rriz JL, Mart\u00ednez-Castelao A, Ortiz A, Mora-Fern\u00e1ndez C. Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease. Diabetes Care. 2018;41(8):1817\u201320. https:\/\/doi.org\/10.2337\/dc18-0078. Epub 2018 Jun 4. PMID: 29866645.","DOI":"10.2337\/dc18-0078"},{"issue":"5","key":"4399_CR42","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s13300-022-01250-y","volume":"13","author":"F Moosaie","year":"2022","unstructured":"Moosaie F, Rabizadeh S, Fallahzadeh A, Sheikhy A, Meysamie A, Dehghani Firouzabadi F, Nakhjavani M, Esteghamati A. Effects of pentoxifylline on serum markers of diabetic nephropathy in type 2 diabetes. Diabetes Ther. 2022;13(5):1023\u201336. https:\/\/doi.org\/10.1007\/s13300-022-01250-y. Epub 2022 Apr 5. PMID: 35380410; PMCID: PMC9076784.","journal-title":"Diabetes Ther"},{"key":"4399_CR43","doi-asserted-by":"publisher","unstructured":"Ghorbani A, Omidvar B, Beladi-Mousavi SS, Lak E, Vaziri S. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. Nefrologia. 2012;32(6):790-6. https:\/\/doi.org\/10.3265\/Nefrologia.pre2012.Jun.11242. PMID: 23169362.","DOI":"10.3265\/Nefrologia.pre2012.Jun.11242"},{"key":"4399_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-2369-9-8","volume":"9","author":"DW Johnson","year":"2008","unstructured":"Johnson DW, Hawley CM, Rosser B, Beller E, Thompson C, Fassett RG, Ferrari P, MacDonald S, Pedagogos E, Cass A. Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. BMC Nephrol. 2008;9:8.","journal-title":"BMC Nephrol"},{"issue":"7","key":"4399_CR45","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1097\/01.ASN.0000131523.17045.56","volume":"15","author":"A Cooper","year":"2004","unstructured":"Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol. 2004;15(7):1877\u201382.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4399_CR46","doi-asserted-by":"publisher","first-page":"e0119578","DOI":"10.1371\/journal.pone.0119578","volume":"10","author":"S Fukuda","year":"2015","unstructured":"Fukuda S, Koyama H, Kondo K, Fujii H, Hirayama Y, Tabata T, Okamura M, Yamakawa T, Okada S, Hirata S, Kiyama H, Kajimoto O, Watanabe Y, Inaba M, Nishizawa Y. Effects of nutritional supplementation on fatigue, and autonomic and immune dysfunction in patients with end-stage renal disease: a randomized, double-blind, placebo-controlled, multicentre trial. PLoS ONE. 2015;10(3):e0119578.","journal-title":"PLoS ONE"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04399-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04399-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04399-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T07:09:54Z","timestamp":1757401794000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04399-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4399"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04399-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our research conducted on patients, and also the patients\u2019 data, was done in compliance with the Helsinki Declaration (). Besides, this study\u2019s research was granted authorization by the Research Ethics Committee (REC), Faculty of Medicine, Ain Shams University, No. (FMASU MS UNIV 15\/2022) dated to 15\/12\/2022, and the Ethical Committee in the Faculty of Pharmacy (Girls), Al-Azhar University, No. (313) dated to 22\/12\/2022. This study was authorized by  (NCT05284656) and the first date of registration was 16\/02\/2022.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients were assigned to write an informed consent. A written informed consent has been obtained from each patient to publish this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"468"}}